Preview

User

Not a user? Register with this site Forgot your password?

Patient-Oriented Medicine and Pharmacy

Advanced search

Editorial Policies

Aim and Scope

The concept of patient-oriented in medicine and pharmacy represents a significant shift in the approach to providing medical care, where the key element is the patient with his/her individual needs, preferences and values. This approach emphasizes the importance of the patient's active participation in making decisions about his/her treatment, which corresponds to the slogan: "nothing that concerns me is done without me".

Key aspects of patient-oriented:

1. Personalization of treatment:

Use of personalized and precision medicine technologies, including genomic, epigenomic and metabolomic biomarkers. Development of algorithms for personalization of pharmacotherapy that take into account individual patient characteristics, such as genetic, ethnic and metabolic factors. Implementation of computerized clinical decision support systems that help physicians choose the optimal treatment for each patient.

2. Crisis of evidence-based medicine methodology:

Limitations of traditional clinical trials, which often evaluate the effectiveness of treatment on "average" patients, which does not always reflect real-worl clinical practice. The need to conduct research on real-world data (RWD) and real-world evidence (RWE) that take into account individual patient characteristics and their response to treatment.

3. The role of the patient in decision making:

Active patient participation in the choice of treatment methods, including the use of drugs. Taking into account the patient's preferences, values, and economic capabilities when developing a treatment plan.

4. Patient safety:

Studying tools to ensure safety in the use of drugs, including over-the-counter drugs. Development of pharmaceutical counseling and responsible self-medication.

5. Information technology:

Using digital and mobile technologies to bridge the gap between clinical research and real-world clinical practice. Development of the "mHealth" and "mResearch" areas, which allow collecting data on patients in real time and adapting treatment to their needs.

 

Section Policies

FROM EDITOR-IN-CHIEF
Checked Open Submissions Checked Indexed Checked Peer Reviewed
FROM PUBLISHER
Checked Open Submissions Checked Indexed Checked Peer Reviewed
LEADING ARTICLE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ACTUAL REVIEW
Checked Open Submissions Checked Indexed Checked Peer Reviewed
NEW DRUGS AND HEALTH TECHNOLOGIES
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ORPHAN DRUGS AND DISEASES
Checked Open Submissions Checked Indexed Checked Peer Reviewed
OBSTETRICS AND GYNECOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
IMMUNOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ANESTHESIOLOGY AND RESUSCITATION
Checked Open Submissions Checked Indexed Checked Peer Reviewed
HEMATOLOGY AND TRANSFUSIOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
GERONTOLOGY AND GERIATRICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
INTERNAL MEDICINE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DERMATOVENEROLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PEDIATRIC SURGERY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
INFECTIOUS DISEASES
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CARDIOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CLINICAL LABORATORY DIAGNOSIS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DENTISTRY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOLOGY, CLINICAL PHARMACOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
RADIATION DIAGNOSTICS AND THERAPY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
MEDICAL CYBERNETICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PSYCHIATRY AND NARCOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
NEUROLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
NEPHROLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PUBLIC HEALTH AND HEALTHCARE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ONCOLOGY, RADIATION THERAPY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
OPHTHALMOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
OTORHINOLARYNGOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PALLIATIVE CARE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PEDIATRICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PLASTIC SURGERY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PULMONOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
RHEUMATOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CARDIOVASCULAR SURGERY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
TRAUMATOLOGY AND ORTHOPEDICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
UROLOGY AND ANDROLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHYSICAL AND REHABILITATION MEDICINE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHTHISITRY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
SURGERY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ENDOCRINOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
EPIDEMIOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DRUG PROVISION
Checked Open Submissions Checked Indexed Checked Peer Reviewed
MANAGEMENT AND ECONOMICS OF PHARMACY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DRUG SAFETY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
MEDICAL DEVICE SAFETY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
BIOMEDICAL ETHICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DRUG INTERACTIONS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
QUALITY OF LIFE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DRUGS UTILIZATION RESEARCH
Checked Open Submissions Checked Indexed Checked Peer Reviewed
REAL-WORLD STUDIES
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CLINICAL TRIALS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
HEALTH TECHNOLOGY ASSESSMENT
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PERSONALIZED MEDICINE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOGENETICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOVILIGANCE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOECONOMICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOEPIDEMIOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PRACTICAL RECOMMENDATIONS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
EXPERT OPINIONS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
SOFTWARE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
EDUCATION
Checked Open Submissions Checked Indexed Checked Peer Reviewed
HISTORY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
BOOKSHELF
Checked Open Submissions Checked Indexed Checked Peer Reviewed
MESSAGE FROM COMPANY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ANNIVERSARY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
IN MEMORIAL
Checked Open Submissions Checked Indexed Checked Peer Reviewed
SYSTEMATIC REVIEW AND META-ANALYSIS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PSYCHOTHERAPY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
UROLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
RATIONAL PHARMACOTHERAPY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
BOOK REVIEW
Checked Open Submissions Checked Indexed Checked Peer Reviewed
HISTORY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOGNOSY AND PHARMACEUTICAL TECHNOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
OBITUARY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACEUTICAL CHEMISTRY, PHARMACOGNOSY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACY BUSINESS ORGANIZATION
Checked Open Submissions Checked Indexed Checked Peer Reviewed
FORENSIC MEDICINE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DIGITAL MEDICINE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CLINICAL PHARMACOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CLINICAL PSYCHOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ONCOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
 

Peer Review Process

All scientific articles submitted to the editors of the journal "Patient-Oriented Medicine and Pharmacy" undergo mandatory two-sided anonymous (“blind”) peer review (the authors of the manuscript do not know the reviewers and receive a letter with comments signed by the editor-in-chief or scientific editor).

Articles reviewed by invited reviewers - leading experts in the relevant fields of medicine and pharmacy in Russia and other countries. The decision to choose one or another reviewer for the examination of the article is made by the editor-in-chief, deputy editor-in-chief, scientific editor, editorial manager. The review period is 8 weeks, but at the request of the reviewer, it can be extended.

Each article is sent to 2 reviewers.

Each reviewer has the right to refuse a review if there is a clear conflict of interest that affects the perception and interpretation of the manuscript material. Based on the results of reviewing the manuscript, the reviewer makes recommendations on the future fate of the article (each decision of the reviewer is justified):

  • The article is recommended for publication in its present form;
  • The article is recommended for publication after the shortcomings noted by the reviewer are corrected;
  • The article needs additional review by another specialist;
  • This article cannot be published in a journal.

If the review contains recommendations for correcting and refining the article, the editors of the journal send the author the text of the review with a proposal to take them into consideration when preparing a new version of the article or to refute them with reason (partially or completely). Finalization of the article should not take more than two months from the date of e-mailing the authors about the need to make changes. This article modified by the author is re-sent for review.

If the authors refuse to finalise the materials, they must notify the editors in writing or orally of their refusal to publish the article. If the authors do not return the revised version after 3 months from the date of sending the review, even in the absence of information from the authors with a refusal to finalise the article, the editors remove it from the register. In such situations, the authors are sent a corresponding notice of the removal of the manuscript from registration due to the expiration of the time allotted for revision.

If the author and reviewers have irresolvable contradictions regarding the manuscript, the editorial board has the right to send the manuscript for additional review. In conflict situations, the decision is made by the editor-in-chief at a meeting of the editorial board.

The decision to refuse the publication of the manuscript was made at a meeting of the editorial board in accordance with the recommendations of the reviewers. An article not recommended by the decision of the editorial board for publication is not accepted for re-consideration. A notice of refusal to publish was sent to the author by e-mail.

After the editorial board of the journal decides on the admission of the article for publication, the editorial board informs the author about this and indicates the terms of publication.

The presence of a positive review is not sufficient grounds for publishing an article. The final decision on publication is made by the editorial board. In conflict situations, the decision is made by the editor-in-chief.

The original reviews are stored in the editorial office of the journal for 5 years.

 

Publication Frequency

The journal "Patient-Oriented Medicine and Pharmacy" publishes 4 issues per year. Articles in each issue are distributed as they are ready and in the order they are received by the editorial board.

 

Open Access Policy

This is an open access journal. All articles are made freely available to readers immediatly upon publication.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition - it means that articles have free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself.

For more information please read BOAI statement.

 

 

Archiving

  • National Electronic Information Consortium (NEICON)​​​​​​​
  • Russian Scientific Electronic Library
  • Elibrary
  • CyberLeninka
  • RSL Russian State Library

 

Peer-Review

A double-blind peer review method is mandatory for processing of all scientific manuscripts submitted to the editorial stuff of "Patient-Oriented Medicine and Pharmacy". This implies that neither the reviewer is aware of the authorship of the manuscript, nor the author maintains any contact with the reviewer. The manuscripts are sent to two reviewers for evaluation.

  1. Leading Russian and international experts in corresponding areas of life sciences, invited as independent readers, perform peer reviews. Editor-in-chief, deputy editor-in-chief or science editor choose readers for peer review. We aim to limit the review process to 8 weeks, though in some cases the schedule may be adjusted at the reviewer’s request.
  2. Reviewer has an option to abnegate the assessment should any conflict of interests arise that may affect perception or interpretation of the manuscript. Upon the scrutiny, the reviewer is expected to present the editorial board with one of the following recommendations:
    - to accept the paper in its present state;
    - to invited the author to revise their manuscript to address specific concerns before final decision is reached;
    - that final decision be reached following further reviewing by another specialist;
    - to reject the manuscript outright.
  3. If the reviewer has recommended any refinements, the editorial staff would suggest the author either to implement the corrections, or to dispute them reasonably. Authors are kindly required to limit their revision to 2 months and resubmit the adapted manuscript within this period for final evaluation.
  4. We politely request that the editor be notified verbally or in writing should the author decide to refuse from publishing the manuscript. In case the author fails to do so within 3 months since receiving a copy of the initial review, the editorial board takes the manuscript off the register and notifies the author accordingly.
  5. If author and reviewers meet insoluble contradictions regarding revision of the manuscript, the editor-in-chief resolves the conflict by his own authority.
  6. The editorial board reaches final decision to reject a manuscript on the hearing according to reviewers’ recommendations, and duly notifies the authors of their decision via e-mail. The board does not accept previously rejected manuscripts for re-evaluation.
  7. Upon the decision to accept the manuscript for publishing, the editorial staff notifies the authors of the scheduled date of publication.
  8. Kindly note that positive review does not guarantee the acceptance, as final decision in all cases lies with the editorial board. By his authority, editor-in-chief rules final solution of every conflict.
  9. Original reviews of submitted manuscripts remain deposited for 5 years.

 

Publishing Ethics

The Publication Ethics and Publication Malpractice Statement of the journal "Patient-Oriented Medicine and Pharmacy" are based on the Committee on Publication Ethics (COPE) Code of Conduct guidelines available at www.publicationethics.org,  and requirements for peer-reviewed journals, elaborated by the "Elsevier" Publishing House (in accordance with international ethical rules of scientific publications)

The Publication Ethics and Publication Malpractice Statement of the journal "Patient-Oriented Medicine and Pharmacy" are based on the Committee on Publication Ethics (COPE) Code of Conduct guidelines available at www.publicationethics.org,  and requirements for peer-reviewed medical journals ((http://health.elsevier.ru/attachments/editor/file/ethical_code_final.pdf), elaborated by the "Elsevier" Publishing House (in accordance with international ethical rules of scientific publications) 

1. Introduction

1.1. The publication in a peer reviewed learned journal, serves many purposes outside of simple communication. It is a building block in the development of a coherent and respected network of knowledge. For all these reasons and more it is important to lay down standards of expected ethical behaviour by all parties involved in the act of publishing: the author, the journal editor, the peer reviewer, the publisher and the society for society-owned or sponsored journal: "Patient-Oriented Medicine and Pharmacy"

1.2.Publisher has a supporting, investing and nurturing role in the scholarly communication process but is also ultimately responsible for ensuring that best practice is followed in its publications.

1.3. Publisher takes its duties of guardianship over the scholarly record extremely seriously. Our journal programmes record «the minutes of science» and we recognise our responsibilities as the keeper of those «minutes» in all our policies not least the ethical guidelines that we have here adopted.

2. Duties of Editors

2.1.Publication decision – The Editor of a learned "Patient-Oriented Medicine and Pharmacy" is solely and independently responsible for deciding which of the articles submitted to the journal should be published, often working on conjunction with the relevant society (for society-owned or sponsored journals). The validation of the work in question and its importance to researchers and readers must always underwrite such decisions. The Editor may be guided by the policies of the "Patient-Oriented Medicine and Pharmacy" journal’s editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editor may confer with other editors or reviewers (or society officers) in making this decision.

2.2.Fair play – An editor should evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.

2.3.Confidentiality – The editor and any editorial staff of "Patient-Oriented Medicine and Pharmacy" must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.

2.4.Disclosure and Conflicts of interest

2.4.1. Unpublished materials disclosed in a submitted manuscript must not be used in an editor’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

2.4.2. Editors should recuse themselves (i.e. should ask a co-editor, associate editor or other member of the editorial board instead to review and consider) from considering manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or (possibly) institutions connected to the papers.

2.5.Vigilance over published record – An editor presented with convincing evidence that the substance or conclusions of a published paper are erroneous should coordinate with the publisher (and/or society) to promote the prompt publication of a correction, retraction, expression of concern, or other note, as may be relevant.

2.6.Involvement and cooperation in investigations – An editor should take reasonably responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper, in conjunction with the publisher (or society). Such measures will generally include contacting the author of the manuscript or paper and giving due consideration of the respective complaint or claims made, but may also include further communications to the relevant institutions and research bodies.

3.    Duties of Reviewers

3.1.Contribution to Editorial Decisions – Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper. Peer review is an essential component of formal scholarly communication, and lies at the heart of the scientific method. Publisher shares the view of many that all scholars who wish to contribute to publications have an obligation to do a fair share of reviewing.

3.2.Promptness – Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor of "Patient-Oriented Medicine and Pharmacy" and excuse himself from the review process.

3.3.Confidentiality – Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorised by the editor.

3.4.Standard and objectivity – Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.

3.5.Acknowledgement of Sources – Reviewers  should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor’s attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.

3.6.Disclosure and Conflict of Interest

3.6.1.Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

3.6.2. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

4. Duties of Authors

4.1.Reporting standards

4.1.1. Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behaviour and are unacceptable.

4.1.2. Review and professional publication articles should also be accurate and objective, and editorial 'opinion’ works should be clearly identified as such.

4.2.Data Access and Retention – Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

4.3.Originality and Plagiarism

4.3.1. The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others, this has been appropriately cited or quoted.

4.3.2. Plagiarism takes many forms, from ‘passing off’ another’s paper as the author’s own paper, to copying or paraphrasing substantial parts of another’s paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behaviour and is unacceptable.

4.4.Multiple, Redundant or Concurrent Publication

4.4.1. An author should not in general publish manuscripts describing essentially the same research in more than one journal of primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behaviour and is unacceptable.

4.4.2. In general, an author should not submit for consideration in another journal a previously published paper.

4.4.3. Publication of some kinds of articles (eg, clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication. Further detail on acceptable forms of secondary publication can be found at www.icmje.org.

4.5.Acknowledgement of Sources – Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.

4.6.Authorship of the Paper

4.6.1. Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors.

4.6.2. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

4.7.Hazards and Human or Animal Subjects

4.7.1. If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.

4.7.2. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

4.8. Disclosure and Conflicts of Interest

4.8.1. All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.

4.8.2. Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest possible stage.

4.9. Fundamental errors in published works – When an author discovers a significant error or inaccuracy in a published work, it is the author’s obligation to promptly notify the editor of "Patient-Oriented Medicine and Pharmacy" journal and cooperate with Publisher to retract or correct the paper, If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper.

5. Duties of the Publisher (and if relevant, Society)

5.1. Publisher should adopt policies and procedures that support editors, reviewers and authors of "Patient-Oriented Medicine and Pharmacy" in performing their ethical duties under these ethics guidelines. The publisher should ensure that the potential for advertising or reprint revenue has no impact or influence on editorial decisions.

5.2. The publisher should support "Patient-Oriented Medicine and Pharmacy" journal editors in the review of complaints raised concerning ethical issues and help communications with other journals and/or publishers where this is useful to editors.

5.3. Publisher should develop codes of practice and inculcate industry standards for best practice on ethical matters, errors and retractions.

5.4. Publisher should provide specialised legal review and counsel if necessary.

The section is prepared according to the files (http://health.elsevier.ru/attachments/editor/file/ethical_code_final.pdf) of Elsevier publisher (https://www.elsevier.com/) and files (http://publicationethics.org/resources) from Committee on Publication Ethics (COPE - http://publicationethics.org/). 

 

 

Founder

 

Article processing charge

Since January 1, 2026, publication of scientific articles in the journal "Patient-Oriented Medicine and Pharmacy" is subject to a fee and is subject to payment of an article processing charge (APC). This fee covers the process of updating submitted manuscripts to international guidelines for authors, a process that requires significant editorial time and resources. Thanks to the APC, all articles published in the journal are openly accessible immediately after publication. The APC covers scientific editing, technical editing and proofreading, article layout, website posting, indexed databases and repositories, and author engagement.

Free article publication. High-quality articles (research of national or international standing) may be eligible for free publication at the discretion of the editorial board. We review requests for exceptions to the rules and make individual decisions on a case-by-case basis. In particular, the article processing fee is waived for the sole author of an article who is a graduate student at a Russian state university. In this case, a cover letter—a publication referral from the research institution on the institution's letterhead and signed by an official—is required. Please submit your request for an exception to these guidelines when submitting your manuscript. A decision is typically made within two business days. Requests submitted after the initial review or during the peer review process will not be considered.

Before submitting your article to the editor, please read not only the Author Guidelines but also the editorial and publishing fee terms.

Payment of the editorial and publishing fee is made after the article has been reviewed and accepted for publication by the journal's editorial board by transferring funds to the bank account of OKI Publishing House LLC. The article must not be advertising in nature and must not contain trade names of drugs or medical devices, nor information about grant support or other forms of funding.

Publication of scientific articles in the journal "Patient-Oriented Medicine and Pharmacy" is subject to payment of the editorial and publishing fee of 10,000 rubles per article.

To pay the editorial and publishing fee as an individual, please follow the link: Payment of the editorial and publishing fee in the journal "Patient-Oriented Medicine and Pharmacy."

As confirmation of payment, you will receive a receipt from Yandex OFD to the email address you provided. This is an official document that can be submitted to your organization's accounting department for reimbursement of expenses.

After payment, please notify the editorial staff by email at eva88@list.ru, indicating the title of the publication, and your article will be sent for further processing and preparation for publication.

These rates are for individuals only, provided payment is made by credit card. Payment by legal entities is subject to different terms; it is also possible that an agreement between the legal entity and the publisher has already been concluded. If authors intend to make payment from a legal entity's account, please indicate this when submitting the manuscript. To pay from a legal entity, please send a request and the organization's bank details to eva88@list.ru to receive an invoice for the editorial and publishing fee. After you provide a copy of the payment receipt to the editorial staff, the article will be sent for further processing and preparation for publication.

Payment for retracted articles is non-refundable.

__________________

Fast Track Publication. After the manuscript has been peer-reviewed and accepted for publication by the editors, it will be published in the next issue of the journal. This service includes the following:

  • Technical preparation of the manuscript for peer review.
  • Expedited peer review.
  • Publication in electronic format online on the journal's website in the "Accepted for publication" section ("Online First").
  • Priority publication in the next upcoming issue of the journal.

The fee for this service is 20,000 (twenty thousand) rubles per work.

Payment procedure: After the manuscript has successfully passed the peer-review stage ("recommended for publication"), the editor sends the corresponding author a letter with the results. While the manuscript is being revised based on the reviewers' and editor's comments, the author can notify the editors of their choice of the "Expedited Publication" service and make payment. Upon receipt of payment, the article approved by the editors and corresponding author is posted in PDF format on the journal's website in the "Online First" section prior to publication in the print issue, and is also included in the next upcoming print issue. The service is considered rendered upon publication of the print issue containing the authors' article.

To pay for urgent publication ("Fast Track") by an individual, please follow the link below:
Fast Track fee for publishing an article in the journal "Patient-Oriented Medicine and Pharmacy."

__________________

This offer is a public offer.

November 5, 2025, Moscow

 

Disclosure and Conflict of Interest

Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

 

Plagiarism detection

"Patient-Oriented Medicine and Pharmacy" use native russian-language plagiarism detection software Antiplagiat to screen the submissions. If plagiarism is identified, the COPE guidelines on plagiarism will be followed.

 

Preprint and postprint Policy

Prior to acceptance and publication in "Patient-Oriented Medicine and Pharmacy", authors may make their submissions available as preprints on personal or public websites.

As part of submission process, authors are required to confirm that the submission has not been previously published, nor has been submitted. After a manuscript has been published in "Patient-Oriented Medicine and Pharmacy" we suggest that the link to the article on journal's website is used when the article is shared on personal or public websites.

Glossary (by SHERPA)

Preprint - In the context of Open Access, a preprint is a draft of an academic article or other publication before it has been submitted for peer-review or other quality assurance procedure as part of the publication process. Preprints cover initial and successive drafts of articles, working papers or draft conference papers.
 
Postprint - The final version of an academic article or other publication - after it has been peer-reviewed and revised into its final form by the author. As a general term this covers both the author's final version and the version as published, with formatting and copy-editing changes in place.

 

Revenue Sources

The publication of the journal is financed by the funds of the parent organization, at the expense of the publisher, publication of advertising materials, publication of reprints, article processment charges.

 

Policy on revocation or correction of articles

Editors should consider retracting a publication if:

  • They have clear evidence that the findings are unreliable, either as a result of major error (eg, miscalculation or experimental error), or as a result of fabrication (eg, of data) or falsification (eg, image manipulation)
  • It constitutes plagiarism
  • The findings have previously been published elsewhere without proper attribution to previous sources or disclosure to the editor, permission to republish, or justification (ie, cases of redundant publication)
  • It contains material or data without authorisation for use
  • Copyright has been infringed or there is some other serious legal issue (eg, libel, privacy)
  • It reports unethical research
  • It has been published solely on the basis of a compromised or manipulated peer review process
  • The author(s) failed to disclose a major competing interest (a.k.a. conflict of interest) that, in the view of the editor, would have unduly affected interpretations of the work or recommendations by editors and peer reviewers.

Notices of retraction should:

  • Be linked to the retracted article wherever possible (ie, in all online versions)
  • Clearly identify the retracted article (eg, by including the title and authors in the retraction heading or citing the retracted article)
  • Be clearly identified as a retraction (ie, distinct from other types of correction or comment)
  • Be published promptly to minimise harmful effects
  • Be freely available to all readers (ie, not behind access barriers or available only to subscribers)
  • State who is retracting the article
  • State the reason(s) for retraction
  • Be objective, factual and avoid inflammatory language.

Retractions are not usually appropriate if:

  • The authorship is disputed but there is no reason to doubt the validity of the findings
  • The main findings of the work are still reliable and correction could sufficiently address errors or concerns
  • An editor has inconclusive evidence to support retraction, or is awaiting additional information such as from an institutional investigation (for information about Expressions of Concern see https://publicationethics.org/expressions-of-concern-forum-discussion)
  • Author conflicts of interest have been reported to the journal after publication, but in the editor’s view these are not likely to have influenced interpretations or recommendations or the conclusions of the article.

For more information: COPE (Version 2: November 2019)

https://publicationethics.org/files/retraction-guidelines.pdf 

 

Personal data processing policy

Information about the authors (last name, first name, patronymic, name of the affiliated organization, e-mail address for readers to contact the author) provided by them for publication in the journal becomes available to an indefinite number of persons, to which the authors give written consent by the fact of the Offer concept when uploading the article to the online article acceptance system on the journal’s website. The publication of this information is carried out in the interests of the authors for the purpose of full and correct accounting of publications and their citation by the relevant bibliographic organizations and ensuring the possibility of contacts between authors and the scientific community.

Personal information provided by the authors to the journal in addition to the above information, including additional e-mail addresses and phone numbers, will be used exclusively for contacts with the authors during the preparation of the article for publication. The editorial board does not transfer this personal information to third parties who may use it for other purposes.

 

Policy on Generative Artificial Intelligence

1. General principles
The journal recognizes that generative and other artificial intelligence (AI) tools can serve as useful aids in manuscript preparation but they do not replace scholarly expertise, critical thinking, or accountability of researchers. Responsibility for the content of the manuscript, including text, data, images, code, and references, rests solely with the human authors listed on the article.​

2. Authorship and the role of AI
AI tools (including language models, image generators, code assistants, and similar systems) cannot be considered authors and must not be listed as authors or co‑authors. Authors must not delegate scientifically significant decisions (such as formulating hypotheses, interpreting results, drawing conclusions, or making recommendations) to AI systems without their own critical assessment and control.​

3. Acceptable uses of AI
AI may be used as a supporting tool, including for:

  • language editing and stylistic improvement of text already written by the authors;
  • assistance in structuring the manuscript and formulating titles and abstracts;
  • checking spelling, grammar, and basic formatting;
  • technical assistance with preparing cover letters and peer‑review reports.​

In all cases, authors must carefully review and, where necessary, correct AI outputs to avoid factual errors, distortion of meaning, plagiarism, or inaccurate references.​

4. Unacceptable uses of AI
The use of AI is strictly prohibited for:

  • generating, modifying, or “enhancing” research data, images, figures, or code that are presented as genuine research results;
  • fabrication, falsification, or concealment of data, as well as creating “illustrative” data instead of actually obtained results;
  • generating text that is presented as entirely original scholarly contribution without substantial revision and verification by the authors;
  • automatic generation, invention, or distortion of bibliographic references.​

AI tools must not be used to circumvent peer‑review processes, to simulate peer‑review reports, or to present others’ ideas as one’s own.​

5. Disclosure of AI use
Any substantial use of generative AI in preparing the manuscript must be clearly disclosed in a dedicated statement (for example, in an “AI use disclosure statement”, “Acknowledgements”, or a similar section) with a brief description of:

  • which tools were used (including provider and version, where possible);
  • at which stage and for what purpose (for example, “language editing of the Discussion section”, “assistance with structuring the Introduction”).​

Disclosure of AI use does not exempt authors from responsibility for the completeness, accuracy, and integrity of the data and conclusions presented.​

6. Policy for reviewers and editors
Reviewers and editors may use AI tools only as auxiliary aids (for example, for language editing of their own review text, checking structure, or enhancing clarity) provided that:

  • the confidentiality of manuscripts and reviews is strictly preserved (confidential material must not be uploaded to public AI services);
  • they retain full control over the content, tone, and accuracy of the review or editorial correspondence.​

The use of AI to automatically generate peer‑review reports, editorial decisions, or recommendations on manuscripts is not permitted.​

7. Confidentiality, data protection, and copyright
When using AI tools, authors, reviewers, and editors must:

  • refrain from uploading confidential or personal data to public AI services without a proper legal basis and, where necessary, informed consent;
  • respect copyright and third‑party rights and not use AI to create derivative works that infringe intellectual property.​

Authors are responsible for ensuring that all illustrations, tables, and other materials created with the assistance of AI do not infringe third‑party rights and comply with the journal’s ethical and copyright standards.​

8. Violations and consequences
Violations of this AI policy are treated as potential breaches of publication ethics (including, but not limited to, data fabrication, plagiarism, non‑disclosure of relevant information, or misleading the editorial office and readers). Depending on severity, the journal may take actions ranging from requests for clarification and manuscript correction to rejection, retraction of a published article, and notification of the authors’ institutions or relevant ethics bodies.

 

Authorship Policy and Contribution Statement

The journal adheres to strict principles of research ethics and follows international standards (ICMJE, COPE) in determining authorship and contributor roles.

Authorship Criteria

To be listed as an author, one must have made a significant intellectual contribution to the study, including:

  • Participation in research conception and design.
  • Data collection, analysis, or interpretation.
  • Drafting or critically revising the manuscript.
  • Approval of the final version for publication.

The following do not qualify for authorship:

  • Funding acquisition alone.
  • Provision of materials or technical assistance only.
  • General supervision without direct scientific input.

Authorship Order

  • Author order should reflect relative contributions (first author = primary researcher, last author = senior supervisor).
  • All authors must approve the submitted manuscript and take responsibility for its content.
  • Changes to the author list after submission require written consent from all authors and editorial approval.

Author Responsibilities

Each author must:

  • Disclose their specific contributions (using CRediT – Contributor Roles Taxonomy).
  • Justify the inclusion of all co-authors and explain any omissions.
  • Cooperate in resolving authorship disputes.

Special Cases

  • Group authorship (consortia, collaborations) – must specify the group’s role and a contact person.
  • Non-author contributors (e.g., statistical support) – should be acknowledged in the "Acknowledgements" section with their consent.

Disputes and Violations

  • Authorship disputes will be investigated by the editorial board (drafts, correspondence, or lab records may be requested).
  • Unjustified inclusion/exclusion of authors may lead to manuscript rejection or retraction.
  • "Guest" or "gift" authorship (adding non-contributors) is prohibited and considered unethical.

Contribution Statement

Upon submission, authors must complete a "Contributor Roles" form (e.g., following CRediT standards), detailing:

  • Conceptualization – Idea formulation; overarching research goals.
  • Data Curation – Managing, annotating, and archiving research data.
  • Formal Analysis – Applying statistical/mathematical/computational techniques.
  • Funding Acquisition – Securing financial support for the project.
  • Investigation – Conducting experiments/data collection.
  • Methodology – Designing research methods and protocols.
  • Project Administration – Overseeing research planning and execution.
  • Resources – Providing materials, tools, or infrastructure.
  • Software – Developing, programming, or testing software.
  • Supervision – Leading and mentoring the research team.
  • Validation – Verifying reproducibility and accuracy of results.
  • Visualization – Preparing figures, diagrams, or presentations.
  • Writing – Original Draft – Creating the first manuscript version.
  • Writing – Review & Editing – Revising and refining the manuscript.

These roles help clarify individual contributions in multi-author papers, improving transparency in academic publishing. The journal reserves the right to request additional clarification on authorship at any stage of peer review.

This policy aligns with ICMJE (International Committee of Medical Journal Editors) and COPE (Committee on Publication Ethics) guidelines.

 

Complaints and Appeals Policy

The journal is committed to maintaining fairness, transparency, and objectivity in handling all complaints and appeals. This policy follows COPE (Committee on Publication Ethics) guidelines and international standards of scholarly publishing.

Types of Complaints Considered

The journal will review:

  • Appeals of editorial decisions (rejection, revision requests)
  • Allegations of publication ethics violations
  • Concerns about peer review quality
  • Conflicts between authors, reviewers, and editors
  • Accusations of plagiarism or data fabrication

Submission Process

  1. Complaints must be sent to the Editor-in-Chief via the journal's official email: clinvest@mail.ru.
  2. The complaint should include:
  • Manuscript ID (number) in the publication system, article title, article authors (if applicable)
  • Detailed description of the issue
  • Supporting evidence and materials
  • Complainant's contact information

Review Procedure

Initial Assessment (3 business days):

  • Acknowledgement of receipt
  • Evaluation of complaint validity

Formal Investigation (15-30 business days):

  • Formation of an independent review panel
  • Collection of additional information
  • Comprehensive case examination

Decision Making:

  • Panel reaches a conclusion
  • All parties receive notification
  • Retraction may be initiated for serious violations

Possible Outcomes

  • Reversal of publication decision
  • Additional peer review
  • Publication of corrections/retractions
  • Article retraction
  • Temporary or permanent bans for violators

Special Cases

  • Anonymous complaints require substantial evidence
  • Conflicts of interest must be fully disclosed
  • Repeat complaints without new evidence won't be reconsidered

Complainant Rights

  • Receive a written response with rationale
  • Request reconsideration with new evidence
  • Escalate to COPE or publisher if dissatisfied

The journal ensures confidentiality and impartiality throughout the process. Typical resolution time is 20 business days (up to 60 for complex cases).

Policy last updated: 11.04.2025.

 

Conflict of Interest Policy

A conflict of interest exists when professional judgment concerning primary interests (research validity) may be potentially influenced by secondary interests (financial gain, personal relationships, academic competition). Competing interests include any financial or non-financial factors that could affect the interpretation or presentation of results.

Author Responsibilities

All authors must:

  • Disclose all potential conflicts of interest upon manuscript submission
  • Declare all research funding sources
  • Report any financial or personal relationships with organizations/individuals that could be interested in the research outcomes
  • Include a conflict of interest statement in a dedicated manuscript section

Reviewer Responsibilities

Reviewers must:

  • Decline to review manuscripts where conflicts exist
  • Disclose any relationships with authors that might affect objectivity
  • Refrain from using unpublished manuscript information for personal benefit

Editorial Responsibilities

The editorial board will:

  • Evaluate declared conflicts of interest
  • Determine necessary disclosure actions
  • Reserve the right to reject submissions with undisclosed significant conflicts
  • Ensure editorial process objectivity

Types of Conflicts

Financial:

  • Research grants and funding
  • Consultancy agreements
  • Stock ownership or patents
  • Paid lectures

Non-financial:

  • Personal relationships
  • Academic competition
  • Intellectual biases
  • Political/religious beliefs

Disclosure Procedure

All participants must complete a disclosure form including:

  • All funding sources
  • Financial and non-financial interests
  • Any other circumstances potentially constituting conflicts

Conflict of Interest Disclosure Form

(For Authors, Reviewers, and Editors of Medical Journals)

Journal: ___________________________________________________
Manuscript Title: __________________________________________
Date of Completion: ________________________________________

Financial Interests

Please check all applicable options:

  • Grants/Funding:
  • Received grants from organizations related to the research topic
  • Specify source: _______________________________
  • Personal Payments:
  • Consulting fees
  • Honoraria for lectures/presentations
  • Expert testimony payments
  • Specify organization: _______________________________
  • Stocks/Patents:
  • Ownership of stocks/options in companies related to the research
  • Patents (pending/issued) for technologies/drugs mentioned in the work
  • Specify details: _______________________________
  • Other Funding:
  • Compensation for study participation
  • Travel/accommodation expenses for conferences
  • Other (specify): _______________________________

Non-Financial Interests

  • Academic/Professional Relationships:
  • Personal/family relationships with authors, reviewers, or editors
  • Competing research projects
  • Membership in advisory boards/associations
  • Intellectual Preferences:
  • Commitment to specific methodologies/theories
  • Public stance on controversial issues related to the topic
  • Other:
  • Political/religious beliefs that may influence data interpretation
  • Other (specify): _______________________________

Declaration

I, _________________________ (Full Name), confirm:

  • No conflicts of interest
  • The presence of conflicts of interest (listed above)

Signature: _________________________
Date: _________________________

Notes:

For pharmaceutically-funded research, additionally specify:

  • Sponsor's role in study design, data collection, and result interpretation.
  • Existence of publication agreements regardless of study outcomes.

The editorial office reserves the right to request supporting documentation.

Non-disclosure may result in manuscript retraction or sanctions per journal policy.

This form complies with ICMJE and COPE guidelines.

Non-Disclosure Consequences

Failure to disclose may result in:

  • Manuscript rejection
  • Article retraction
  • Publication ban
  • Notification to author's institution

Declaration Format

Each publication must contain a "Conflict of Interest" section stating either:

  • The authors declare no conflicts of interest
  • Detailed description of all potential conflicts

Special Cases

Pharmaceutical-funded research requires additional information:

  • Sponsor's role in study design
  • Access to raw data
  • Publication rights

Editorial Board Policy

Editorial members with conflicts must:

  • Recuse themselves from related decision-making
  • Disclose interests prior to discussions
  • Abstain from reviewing affected manuscripts

The journal adheres to ICMJE and COPE guidelines regarding conflicts of interest. This policy undergoes regular review and updates.

This policy applies to all editorial stages – from submission through publication and post-publication discussion. All participants in the publication process are expected to comply fully with these requirements.

Last updated: 11.04.2025.

 

Policy on Data Sharing and Reproducibility

This policy ensures adherence to scientific ethics standards and promotes the advancement of open science. The journal adheres to the principles of open science and strives to ensure transparency, reproducibility, and reliability of published research. This policy outlines the requirements for sharing data, code, and materials necessary for verifying and replicating results.

Data Sharing

Mandatory Data Disclosure
Authors must provide the underlying research data in one of the following formats:

  • Submission to data repositories.
  • Deposition in open databases (if the study involves publicly available datasets).
  • Inclusion in the supplementary materials of the article (if the data volume is small).

Exceptions:

  • Data containing confidential or personally identifiable information may be provided in anonymized form or upon request by the editorial board.
  • In cases of restrictions (e.g., commercial confidentiality, ethical guidelines), authors must justify this in the manuscript.

Data Formats
Data should be submitted in machine-readable formats (CSV, JSON, TXT, XLSX, etc.) with clear documentation (metadata, codebook).

Reproducibility of Results

Provision of Code and Scripts

  • For computational and statistical research, authors must provide source code (R, Python, MATLAB, etc.) in an open repository (GitHub, GitLab, CodeOcean).
  • If proprietary software was used, the version and runtime parameters must be specified.

Methodological Description
Methods should be described in sufficient detail to allow replication of the experiment or analysis.

Reproducibility Verification

  • The editorial board reserves the right to request data and code from authors to verify results.
  • If results cannot be reproduced, the manuscript may be rejected or sent for revision.

Licensing and Data Citation

  • Authors must select an open license (CC BY, CC0) for data and code.
  • If third-party data is used, the source and terms of use must be cited.

Consequences of Non-Compliance

Failure to provide data or code without valid justification may result in:

  • Rejection of the manuscript.
  • Retraction of the publication (if errors or irreproducibility are identified).

Contact Information

For inquiries regarding data sharing, please contact the editorial office: clinvest@mail.ru.

 

Policy on Biomedical Ethical Oversight

This policy governs the ethical aspects of conducting and publishing medical research involving humans, animals, biological materials, and data, ensuring the protection of participants' rights, safety, and confidentiality, and guaranteeing protection of participants' rights, safety, and confidentiality; compliance with international and national regulations; maintenance of trust within the scientific community and society.

The journal adheres to strict principles of biomedical ethics in its publication practices, following international standards, including:

  • WMA Declaration of Helsinki (October 2024);
  • CIOMS Guidelines (Council for International Organizations of Medical Sciences);
  • ICMJE Recommendations (International Committee of Medical Journal Editors);
  • COPE Principles (Committee on Publication Ethics).

When presenting the results of experimental studies involving humans or animals, authors must explicitly state in the relevant section of the manuscript whether the procedures complied with ethical standards.

Ethical Requirements for Human Research

  • All studies involving human participants must be approved by a local or national ethics committee (with approval number provided).
  • For retrospective studies, confirmation of ethical compliance is required.
  • Participants (or their legal representatives) must provide written informed consent (oral consent is permissible only with ethics committee approval if written consent is unattainable).
  • If medical data or biological materials are used, authors must indicate whether consent was obtained for research use.
  • Participant data must be anonymized (identifiable information removed).
  • Compliance with Russia’s Federal Law "On Personal Data" (or equivalent legislation in the study’s country) is mandatory.
  • Research involving children, pregnant women, individuals with mental disorders, or other vulnerable groups requires additional justification for their inclusion and enhanced protective measures.

Ethical Requirements for Animal Research

Experimental studies involving animals must confirm adherence to national and international regulations ensuring humane treatment, including:

  • EAEU Good Laboratory Practice Rules (2016);
  • Russian Ministry of Health Order No. 199n (2016);
  • SanPiN 2.2.1.3218-14 (requirements for animal facilities);
  • GOST 33215-2019 (laboratory animal welfare standards).

Manuscripts must include:

  • The ethics committee approval number for animal research;
  • Measures to minimize suffering (anesthesia, humane euthanasia methods);
  • Justification for animal use (absence of alternative methods).

Authors’ Responsibilities

  • Data integrity: Fabrication, falsification, or image manipulation (e.g., in histology/radiology) is prohibited.
  • Conflict of interest: Authors must disclose financial ties to pharmaceutical companies, equipment manufacturers, or other stakeholders.
  • Plagiarism & duplicate publication: Reusing data (own or others’) without proper citation is forbidden.

Editorial & Reviewer Responsibilities

  • The editorial team verifies ethics committee approval during manuscript review.
  • Reviewers must report suspected ethical violations (e.g., lack of informed consent, animal mistreatment).
  • Editors may request additional documentation (ethics protocols, consent forms) if concerns arise.

Investigation of Violations

If ethical breaches are identified, the journal reserves the right to:

  • Reject the manuscript at any stage;
  • Retract a published article, notifying readers, repositories, and indexing databases;
  • Report to the authors’ institutional ethics committee for further investigation;
  • Impose a submission ban (up to 5 years) on offending authors.

Transparency & Corrections

  • The journal publishes notices, corrections, and retractions if ethical violations are confirmed.
  • Readers and authors may report concerns via email: clinvest@mail.ru.

Effective Date: April 11, 2025.

 

Policy for Post-Publication Discussions and Corrections

The journal is committed to maintaining high standards of scientific publication and ensuring transparency, error correction, and open discussion of published materials. After publication, the following options are available for interaction with authors and readers:

Corrections

  • Minor errors (typos, small inaccuracies in data that do not affect conclusions) – a Corrigendum is published, specifying the changes.
  • Errors introduced by the editorial team/publisher – a Publisher’s Note is issued.
  • Major errors identified by authors or readers that affect the interpretation of results but do not invalidate the main conclusions – an Erratum is published with an explanation of the corrections.

Addenda

  • If authors wish to provide additional significant information clarifying the study (without altering the conclusions), an Addendum may be published.

Comments & Replies

  • Readers may submit a critical comment on an article, which, after peer review, will be published alongside the authors’ response.
  • If the comment reveals serious concerns, the editorial board may initiate a further review of the article.

Article Retraction

An article may be retracted in cases of:

  • Major errors that invalidate the conclusions.
  • Ethical violations (plagiarism, data fabrication, duplicate publication).
  • Unresolved conflicts of interest that were undisclosed at the time of publication.
    A Retraction Notice will be issued, explaining the reasons for retraction.

Updated Versions (Versioning)

  • In exceptional cases (e.g., discovery of new data), an article may be revised and republished as an updated version labeled "Revised Version".

Procedure for Initiating Changes

  • Readers: May submit requests by emailing the editorial office: clinvest@mail.ru.
  • Authors: Must notify the editorial team of any identified errors.
  • Editors: Will make a decision after consulting reviewers and authors.

The journal reserves the right to modify this policy in accordance with COPE (Committee on Publication Ethics) guidelines and international standards of scientific publishing.

Last updated: 11.04.2025.

 

Public offer agreement

  1. This Agreement is a public offer agreement in accordance with paragraph 2 of Article 437 of the Civil Code of the Russian Federation and is concluded between the Limited Liability Company OKI Publishing House (OGRN 1037721010788, INN 7721253233 ) represented by General Director Elena Afanasyeva, hereinafter referred to as the “Publisher”, and an individual interested in concluding the Agreement, the Author of the work, accepting the Publisher’s offer on the terms and conditions specified below.

Acceptance of the offer is a complete and unconditional acceptance of the offer by performing the actions specified in clause 9 of the offer. The author is obliged to fully familiarize himself with this document before performing the specified actions.

  1. The Author, in case of acceptance of the terms and conditions set out in this offer, sends to the Publisher, using the methods specified on the websites https://www.clinvest.ru/, https://www.pomph.ru/, https://www.pharmacokinetica.ru/, https://www.pharmacogenetics-pharmacogenomics.ru/, https://www.myrwd.ru/, https://www.antibiotics-chemotherapy.ru/ and/or in this offer, a work created by the Author (article, essay, review, etc. - hereinafter referred to as the "Work" in the Agreement) for possible subsequent publication in any of the mass media published by the Publisher, other printed publications, or posting on the Internet.
  2. In accordance with the terms of this Agreement, the Author transfers (alienates), and the Publisher accepts the exclusive right in full to the Work created by the Author, sent to the Publisher. The provision of any licenses to the Author is not provided.
  3. The Author guarantees that he created the Work personally, qualitatively, and that during the creation of the Work, the copyright and other rights and freedoms of third parties, including intellectual property rights and personal non-property rights, as well as the current legislation of the Russian Federation, were not violated.
  4. The Author guarantees that he/she has all the necessary powers to conclude this Agreement, and that the Work, as well as the rights to it, have not previously been transferred to anyone or provided for reproduction and/or other use, and will not be transferred in the future.
  5. If the Work sent to the Publisher in accordance with this Agreement contains materials from other authors, the Author undertakes to use such materials to the extent justified by the purpose of citation, and also to indicate the author of such material and the source of borrowing.
  6. The Author provides the Work written in accordance with the publication requirements for authors published on the websites https://www.clinvest.ru/, https://www.pomph.ru/, https://www.pharmacokinetica.ru/, https://www.pharmacogenetics-pharmacogenomics.ru/, https://www.myrwd.ru/, https://www.antibiotics-chemotherapy.ru/ the Author confirms that he/she is familiar with the specified requirements.
  7. The Author guarantees the authenticity of the material provided in the Work and its compliance with the requirements of the current legislation of the Russian Federation, including, but not limited to, the Federal Law "On Advertising", the Federal Law "On Circulation of Medicines", the Federal Law "On Mass Media", other legislation, and bears full responsibility for the content of the Work and for the violation of this guarantee. For all claims of third parties related to the violation of the rights and interests of third parties (including intellectual property rights, as well as personal non-property rights) or current legislation by the Work transferred by the Author, the Author shall be liable, who is obliged to independently and at his own expense settle all claims, suits, other demands of third parties, including authors and holders of related rights (including directly to the Publisher) in relation to the Work or the materials contained therein, as well as claims / orders of government agencies and take all actions depending on him in order to exclude the Publisher from the number of defendants. In the event that the Publisher has incurred any losses in connection with the use of the Work transferred by the Author, the Author undertakes to compensate for such losses in full, including compensation for sanctions imposed on the Publisher by competent authorities.
  8. This Agreement shall be deemed concluded and the exclusive right to the Author's Work shall be deemed transferred (alienated) to the Publisher from the moment the Author sends the Work to the e-mail address: clinvest@mail.ru or eva88@list.ru or transfers it by other means specified on the websites https://www.clinvest.ru/, https://www.pomph.ru/, https://www.pharmacokinetica.ru/, https://www.pharmacogenetics-pharmacogenomics.ru/, https://www.myrwd.ru/, https://www.antibiotics-chemotherapy.ru/.

Sending the Work to the addresses specified in this paragraph / transferring it by other means specified on the websites https://www.clinvest.ru/, https://www.pomph.ru/, https://www.pharmacokinetica.ru/, https://www.pharmacogenetics-pharmacogenomics.ru/, https://www.myrwd.ru/, https://www.antibiotics-chemotherapy.ru/ shall be considered as confirmation of the fact that the Author has read and understood all the terms of this Agreement, the Author's full and unconditional consent to the terms of this Agreement and acceptance of this offer, as well as confirmation of consent to the processing of personal data in accordance with paragraph 19 of this Agreement.

The Publisher shall not be liable for the Author's failure to familiarize himself with this offer, or for the Author's failure to fulfill (late fulfillment) of the obligations stipulated by this offer.

  1. The Publisher makes the decision to publish the Work sent by the Author solely at its own discretion (including publication in any of the mass media published by it, other printed publications, posting on Internet pages). Submitted Works will not be returned.
  2. The Publisher has the right not to publish a Work that has been previously published elsewhere/made public, or that does not meet the requirements of this Agreement and/or current legislation.
  3. The Publisher, at its own discretion, publishes the Work under the name of the Author or under a pseudonym indicated by him, as well as without such indication.
  4. Unless the Work or the accompanying letter to the Work contains information to the contrary, the Author guarantees that he is the sole author of the Work. If the Work is written in co-authorship, the Author undertakes to indicate them in the Work and guarantees that his co-authors have been notified of the terms of this Agreement, have read it and fully accept it, including the terms of transfer of exclusive rights, as well as that the Author is duly authorized by the co-authors to grant rights to the Work to the Publisher on the terms specified in this Agreement. The Author shall resolve all possible disputes arising from a breach of this guarantee independently and at his own expense.
  5. The submission of materials by the Author and their publication by the Publisher is carried out in the interests of both Parties; this Agreement does not provide for any settlements (payment of remuneration to the Author) for materials provided for publication; remuneration is not collected by the Author and is not paid by the Publisher.
  6. No remuneration is provided for the transfer (alienation) of exclusive rights to the Work in full; no remuneration is collected by the Author (co-authors) and is not paid by the Publisher.
  7. The Publisher may offer the Author to revise the Work, the rights to which have been transferred in accordance with this Agreement. The revision shall be carried out by the Author personally. The rights to revision shall also be alienated to the Publisher by the Author without collection or payment of remuneration (on a gratuitous basis) in full, from the moment the revised Work is sent in any way, including by e-mail.
  1. The Publisher has the right to make scientific, literary and proofreading edits to the submitted Work at its own discretion without the consent of the Author, and also to supplement the Author’s Work with other materials, as well as illustrations, etc.
  2. The Author undertakes not to publish the Work anywhere else without the written consent of the Publisher.
  3. The Author, by concluding this Agreement, expresses his full consent to the processing of his personal data: last name, first name, patronymic, education, profession, academic title, academic degree, date of birth, contact telephone number, e-mail address, postal address, registration address, as well as any other information specified by the Author, both in the Work itself and in the cover letter to it).

Processing of personal data means one or a set of actions: collection, creation, recording, systematization, accumulation, clarification, updating, addition, modification, use, extraction, copying, provision, distribution, transfer, provision of access, placement, depersonalization, blocking, destruction, archiving, deletion, storage. The specified actions are performed in various ways, including by means of non-automated, automated, mixed processing and may involve the use of the official website of the Publisher or the relevant publication or another website on the Internet, other information resources, services, including, but not limited to, www.elibrary.ru and others.

The processing of personal data is carried out in order to ensure compliance with the requirements of the legislation of the Russian Federation, the execution and regulation of contractual relations, the fulfillment of obligations under the Agreement, the performance of actions aimed at ensuring a full editorial and publishing cycle when using the Work (including, without limitation, reviewing the Work, preparing and posting the metadata of the Work included in the relevant publication, preparing electronic versions of articles and issues of the relevant publication for posting in the public domain, creating archives of issues of the relevant publication and posting them (including in the public domain), producing and delivering mandatory copies of each issue of the relevant publication to authorized bodies, providing issues of the relevant publication to national and foreign libraries that provide access to scientific information, providing issues of the relevant publication to national and international abstract databases and citation systems), preparing and sending information messages, while the Publisher has the right to process the personal data of the Author, including by entering them into an electronic database, using machine media or via communication channels. They are not used or stored in any other way; after these goals have been achieved or the need to achieve them has been lost, personal data are subject to destruction or depersonalization.

The author confirms the accuracy and completeness of the personal data and, in the event of a change in any part of the personal data, undertakes to send a corresponding notification to the Publisher.

The consent is valid from the moment of its submission indefinitely (including after the expiration of the Agreement), but in any case, before its revocation, it can be revoked by sending a written notice to the postal address: Russian Federation, 115522, Moscow, Moskvorechye St., Bldg. 4, Bldg. 5, Office 129, while the Author understands the possible consequences of sending a notice of revocation of consent to the processing of personal data.

  1. The author gives his consent to receive notifications, other messages and email newsletters to personal means of communication, which he has the right to revoke at any time in accordance with the rules in paragraph 19 of the Agreement.
  2. If one of the Parties fails to fulfill or improperly fulfills any of the obligations assumed under this Agreement, it shall bear liability for this in accordance with the current legislation of the Russian Federation. The imposition of penalties is a right, not an obligation, of the Parties.
  3. All disputes and disagreements that may arise between the Parties on issues that have not been resolved in the text of this Agreement will be resolved through negotiations based on the current legislation of the Russian Federation. If the disputes are not resolved in the process of negotiations, the disputes will be resolved in court at the location of the Publishing House.
  4. The Parties shall not be liable for the full or partial failure to fulfill their obligations if the failure to fulfill is a consequence of such circumstances as flood, earthquake and other natural disasters, embargo, war or military actions, etc. The Parties have agreed to consider the following circumstances as exempting from liability: the issuance of an act of a state or municipal body of the Russian Federation making the fulfillment of the Agreement impossible or significantly difficult, as well as the introduction of restrictions, establishment of special regimes, as well as improper fulfillment of obligations by the Publisher's counterparties, not related to improper actions or inactions of the latter, fires, unscheduled shutdowns of water supply, heat supply, electricity, etc.

The Party in respect of which force majeure circumstances or circumstances exempting from liability have occurred is obliged to notify the other Party in writing of the occurrence, expected duration and termination of the above circumstances.

  1. The Author confirms that all the terms of this Agreement are clear to him, and by submitting the Work, he accepts them unconditionally and in full.
  2. In all other respects not provided for by this Agreement, the Parties shall be guided by the current legislation of the Russian Federation.
  3. The text of this offer may be changed at any time by the Publisher unilaterally, and the version posted on the websites is considered current https://www.clinvest.ru/, https://www.pomph.ru/, https://www.pharmacokinetica.ru/, https://www.pharmacogenetics-pharmacogenomics.ru/, https://www.myrwd.ru/, https://www.antibiotics-chemotherapy.ru/. The terms of the Agreement remain unchanged for the Author who accepted the offer before the Publisher makes changes to it.
  4. All communications, including approval of the Work or other materials, the Parties carry out via e-mail. Notifications, approvals, sending of the Work and other materials and other communications regarding the execution of this Agreement sent by e-mail are considered official notifications, confirm the will of the Parties to execute the Agreement and have legal force.
  5. The Publisher does not guarantee the absence of malfunctions and errors in the operation of the site. The Publisher is not responsible for the lack of access to the site in the event of failures in the operation of the Internet or in the operation of communication operators directly servicing the Author; termination (suspension) of work, system failures and other technical problems of the Author's Internet provider; scheduled repair or preventive work; defects or failures of any equipment of the Author; accidents in telecommunication systems and power supply systems; other technical circumstances that prevent the Author's access to the site.                                       
  1. Publisher's details:

LLC "OKI Publishing House"

OGRN 1037721010788

INN 7721253233, KPP 772101001

Legal address: Russian Federation, 121357, Moscow, Vatutina st., 4, bldg. 2, apt. 22

Postal address: Russian Federation, 115522, Moscow, Moskvorechye st., 4, bldg. 5, off. 129

current account 40702810838360029819 in PJSC "SBERBANK OF RUSSIA" MOSCOW

c/s 30101810400000000225

BIC 044525225

e-mail: eva88@list.ru

Version from September 01, 2025 (Moscow, Russian Federation)



115522, Moscow, Moskvorechie str., 4-5-129, LLC Izdatelstvo OKI

Processing of personal data
supported by NEICON (Elpub lab)